Pepsinogen II and Helicobacter Pylori Test in Gastric Cancer

Validation of Serum Pepsinogen II and Helicobacter Pylori Test in the Detection of Gastric Cancer in South Korea

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06301464

Enrollment

24000

Registered

2024-03-08

Start date

2003-03-01

Completion date

2025-12-31

Last updated

2024-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

Gastric cancer, Pepsinogen, Helicobacter pylori

Brief summary

The aim of this study to validate the role of pepsinogens in gastric cancer screening.

Detailed description

Serum pepsinogens (PGs) are the biomarkers for gastric cancer (GC), especially atrophic gastritis which is a precursor of intestinal type GC and severe gastric inflammation which is an indicator for diffuse type GC in young age. So, test for serum PGs can be used to identify high risk patients for GC. The aim of this study is to validate the role of PGs in GC screening. Sera and the data from esophagogastroduodenoscopy and questionnaires are collected from study subjects, and PGs and anti-H. pylori (HP) antibody are measured. Area under the curve and receiver operating characteristic curve are calculated to identify the optimal cutoff values for PGs. To validate the usefulness of PGs to predict risk of GC, the subjects are divided into two groups based on each cut-off value for each PG value. Adjusted odds ratios (ORs) and 95% CIs are calculated using multivariate logistic regression. Risk stratification is conducted by combining each PG value and anti-HP antibody in GC subtype.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Who undergoes serum pepsinogens and anti-H. pylori antibody tests, and esophagogastroduodenoscopy during a health-screening examination at Seoul National University Hospital Gangnam center (SNUHGC) or Seoul National University Bundang Hospital (SNUBH)

Exclusion criteria

* Who do not receive serum pepsinogens or anti-H. pylori antibody studies * Who do not receive esophagogastroduodenoscopy within 3 months before or after the date of serum pepsinogens and anti-H. pylori antibody tests * Subjects with recent proton-pump inhibitor therapy 1 month prior to enrollment * Subjects with prior history of gastrectomy * Subjects with upper gastrointestinal neoplasms other than gastric adenoma/adenocarcinoma * Subjects who do not agree to participate in the study or withdraw his/her consent

Design outcomes

Primary

Measure	Time frame	Description
The level of serum pepsinogens	At the time of enrollment	To compare the level of serum pepsinogens between the two groups

Countries

South Korea

Outcome results